PMID- 24673637
OWN - NLM
STAT- MEDLINE
DCOM- 20150519
LR  - 20220409
IS  - 1937-335X (Electronic)
IS  - 1937-3341 (Print)
IS  - 1937-3341 (Linking)
VI  - 20
IP  - 17-18
DP  - 2014 Sep
TI  - Combined effects of brain-derived neurotrophic factor immobilized 
      poly-lactic-co-glycolic acid membrane with human adipose-derived stem cells and 
      basic fibroblast growth factor hydrogel on recovery of erectile dysfunction.
PG  - 2446-54
AB  - Erectile dysfunction (ED) is the most frequent long-term problem after radical 
      prostatectomy. We aimed to evaluate whether the use of combination therapy with 
      basic fibroblast growth factor (bFGF)-hydrogel on corpus cavernosum and with 
      adipose-derived stem cells (ADSCs) and brain-derived neurotrophic factor 
      (BDNF)-immobilized poly-lactic-co-glycolic acid (PLGA) membrane on the cavernous 
      nerve (CN) could improve erectile function in a rat model of bilateral cavernous 
      nerve crush injury (BCNI). Rats were randomly divided into five groups (n=15 per 
      group): a normal group (N group), a group receiving saline application after 
      bilateral cavernous nerve crush injury (BCNI), a group undergoing bFGF-hydrogel 
      injection in the corpus cavernosum after BCNI (bFGF), a group receiving ADSC 
      application covered with BDNF-membrane after BCNI (ADSC/BDNF), and a group 
      undergoing coadministration of bFGF-hydrogel injection and BDNF-membrane with 
      ADSCs after BDNF (bFGF+ADSC/BDNF). Four weeks postoperatively, the erectile 
      function was assessed by detecting the ratio of intracavernous pressure (ICP) to 
      mean arterial pressure (MAP). Smooth muscle and collagen contents were measured 
      using Masson's trichrome staining. Neuronal nitric oxide synthase (nNOS) 
      expression in the dorsal penile nerve was detected by immunostaining. The protein 
      expression of the alpha-smooth muscle actin (alpha-SMA) and the cyclic guanosine 
      monophosphate (cGMP) level of the corpus cavernosum were quantified by western 
      blot and cGMP assay, respectively. In the bFGF+ADSC/BDNF group, the erectile 
      function was significantly elevated compared with the BCNI and other treated 
      groups and showed a significantly increased smooth muscle/collagen ratio, nNOS 
      content, alpha-SMA expression, and cGMP level. In particular, there were no 
      statistical differences in the ICP/MAP ratio, smooth muscle/collagen ratio, and 
      alpha-SMA and cGMP levels between the bFGF+ADSC/BDNF group and normal group. 
      Application of the BDNF-immobilized PLGA membrane with human ADSC into the CN and 
      bFGF-incorporated hydrogel into the corpus carvernosum improved nearly normal 
      erectile function in a rat model of postprostatectomy ED. This result suggests 
      that a combined application of bFGF+ADSC/BDNF might be a promising treatment for 
      postprostatectomy ED.
FAU - Lee, Seung Hwan
AU  - Lee SH
AD  - 1 Department of Urology, Gangnam Severance Hospital, Yousei University Health 
      System , Seoul, Korea.
FAU - Kim, In Gul
AU  - Kim IG
FAU - Jung, Ae Ryang
AU  - Jung AR
FAU - Shrestha, Kshitiz Raj
AU  - Shrestha KR
FAU - Lee, Jin Ho
AU  - Lee JH
FAU - Park, Ki Dong
AU  - Park KD
FAU - Chung, Byung Ha
AU  - Chung BH
FAU - Kim, Sae Woong
AU  - Kim SW
FAU - Kim, Ki Hean
AU  - Kim KH
FAU - Lee, Ji Youl
AU  - Lee JY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140520
PL  - United States
TA  - Tissue Eng Part A
JT  - Tissue engineering. Part A
JID - 101466659
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Drug Carriers)
RN  - 0 (Nerve Growth Factors)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
SB  - IM
EIN - Tissue Eng Part A. 2016 Jan;22(1-2):194. PMID: 26689906
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/*administration & dosage
MH  - Combined Modality Therapy
MH  - Drug Carriers/chemical synthesis
MH  - Drug Therapy, Combination
MH  - Erectile Dysfunction/etiology/*therapy
MH  - Fibroblast Growth Factor 2/*administration & dosage
MH  - Guided Tissue Regeneration/instrumentation/*methods
MH  - Lactic Acid/*chemistry
MH  - Male
MH  - Nerve Growth Factors/administration & dosage
MH  - Nerve Regeneration/drug effects/physiology
MH  - Peripheral Nerve Injuries/complications/*therapy
MH  - Polyglycolic Acid/*chemistry
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Stem Cell Transplantation/instrumentation/*methods
MH  - Tissue Scaffolds
MH  - Treatment Outcome
PMC - PMC4161192
EDAT- 2014/03/29 06:00
MHDA- 2015/05/20 06:00
PMCR- 2015/09/01
CRDT- 2014/03/29 06:00
PHST- 2014/03/29 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2015/05/20 06:00 [medline]
PHST- 2015/09/01 00:00 [pmc-release]
AID - 10.1089/ten.tea.2013.0495 [pii]
AID - 10.1089/ten.tea.2013.0495 [doi]
PST - ppublish
SO  - Tissue Eng Part A. 2014 Sep;20(17-18):2446-54. doi: 10.1089/ten.tea.2013.0495. 
      Epub 2014 May 20.